Article 1 to 1 out of 1 concerning Vascular Biogenics Ltd.
Crucell Announces PER.C6® Licensing Agreement with Vascular Biogenics(04/05/2005) Crucell N.V. announced that it has signed a PER.C6® research license agreement with Israeli biopharmaceutical company Vascular Biogenics Ltd. The non-exclusive agreement allows Vascular Biogenics to use the PER.C6® cell line for the preparation and ...
Top
